K36 Therapeutics

09/03/2026

To know myeloma is to know the parts of the journey that others may never see.

What do you wish more people understood about living with myeloma or caring for someone with the disease?

Complete the sentence in the comments:

“To know myeloma is to know ______.”

We’re proud to join the International Myeloma Foundation in helping more people .

09/02/2026

September is Prostate Cancer Awareness Month

At , we are advancing research for men with metastatic castration-resistant prostate cancer (mCRPC) through STRIKE-001, a Phase 1 clinical trial evaluating KTX-2001, an investigational oral NSD2 inhibitor.

Learn more about STRIKE-001: https://clinicaltrials.gov/study/NCT07103018

09/02/2026

Blood cancers can be difficult to recognize because early signs, such as persistent fatigue, frequent infections, unexplained weight loss, or night sweats, may be easy to overlook. During Blood Cancer Awareness Month, K36 Therapeutics is helping raise awareness of the symptoms that deserve attention. Knowing what to look for can be an important first step toward speaking with your healthcare provider and getting answers.

Watch and share: https://youtu.be/-j3_TiiFnmg

Blood cancer can affect anyone, and recognising the early warning s...

09/01/2026

September is .

is a cancer of the plasma cells, but living with myeloma is about much more than a diagnosis. It can mean lab results, treatment calendars, bone marrow biopsies, moments of uncertainty, and learning a new medical language.

Throughout this September, we’ll help make myeloma more visible and share information that may help patients better understand the biology of their disease. Because knowing myeloma begins with awareness. Knowing your myeloma begins with asking questions.



Learn more about the MMSET trial: https://myeloma.sparkcures.com/trial/1334/NCT05651932?utm_campaign=mmset&utm_medium=social&utm_source=k36

08/29/2026

September is Blood Cancer Awareness Month.
Multiple myeloma is a cancer of the bone marrow plasma cells, but living with myeloma is about much more than a diagnosis. It can mean lab results, treatment calendars, bone marrow biopsies, moments of uncertainty, and learning a new medical language.

Throughout this September, we’ll help make myeloma more visible and share information that may help patients better understand the biology of their disease. Because knowing myeloma begins with awareness. Knowing your myeloma begins with asking questions.

08/26/2026

Awareness is the first step toward a cure. The more people know about myeloma, the more opportunities there are to ensure:

Earlier diagnosis
Greater access to treatments
More investment in myeloma research
Equity in cancer care

Common symptoms include back or bone pain, unexplained fatigue, and recurrent or persistent infections.

08/25/2026

Great science comes to life through exceptional clinical trial teams.

We’re proud to welcome Dr. Anthony Dominick and the outstanding CTO team at MUSC Hollings Cancer Center to the -MMSET-001 study: Spencer, Lillian, Amanda, Kahleal, Jared, Alaina, Brittany, Matthew, Chelsea, Arianna, Shanta, and Emma.

Their expertise, teamwork, and commitment made the rapid activation of this study possible, helping advance a biology-driven approach for patients with t(4;14) multiple myeloma.

To everyone who contributed, including those not named here, thank you for working tirelessly to bring this trial to patients. We’re excited to see the impact this exceptional team will make!

08/25/2026

The K36 Therapeutics myeloma team is heading to Glasgow for !

We look forward to connecting with investigators, clinicians, researchers, patient advocates, and industry colleagues who share our commitment to advancing new possibilities for people living with multiple myeloma.

Will you be in September 23–26? Contact us at [email protected] to schedule a meeting.

08/24/2026

Blood tests are helpful, but bone marrow testing remains an important way to understand your myeloma and help guide treatment.

Bone marrow testing can help your care team:

Identify high-risk features
Inform treatment decisions
Determine clinical trial eligibility
Better understand your myeloma

Researchers are working to improve blood-based testing and reduce the need for repeat biopsies. We’re not there yet, but progress is being made.

If you have questions about bone marrow testing or your results, talk with your myeloma care team. Your comfort matters, and your team can explain why the information may be important for your care. For more information: https://www.myeloma.org/bone-marrow-tests

08/21/2026

1 in 3 myeloma patients is under the age of 65. Source: International Myeloma Foundation
https://youtu.be/cy51WsgIycE?si=bnKMoN7zPL_LAfYt

September is